Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration.

Cao J, MacPherson TC, Iglesias BV, Liu Y, Tirko N, Yancopoulos GD, Wiegand SJ, Romano C.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1033-1044. doi: 10.1167/iovs.17-22897.

PMID:
29450547
2.

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.

MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.

Angiogenesis. 2016 Jul;19(3):389-406. doi: 10.1007/s10456-016-9515-8. Epub 2016 May 27.

3.

A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition.

Wei K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, Vallon M, Morton L, Lefai E, Simon MC, Maher JJ, Mithieux G, Rajas F, Annes J, McGuinness OP, Thurston G, Giaccia AJ, Kuo CJ.

Nat Med. 2013 Oct;19(10):1331-1337. doi: 10.1038/nm.3295. Epub 2013 Sep 15.

4.

Inhibition of delta-like ligand 4 induces luteal hypervascularization followed by functional and structural luteolysis in the primate ovary.

Fraser HM, Hastings JM, Allan D, Morris KD, Rudge JS, Wiegand SJ.

Endocrinology. 2012 Apr;153(4):1972-83. doi: 10.1210/en.2011-1688. Epub 2012 Feb 14.

5.

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ.

Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6. No abstract available.

6.

Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.

Nork TM, Dubielzig RR, Christian BJ, Miller PE, Miller JM, Cao J, Zimmer EP, Wiegand SJ.

Arch Ophthalmol. 2011 Aug;129(8):1042-52. doi: 10.1001/archophthalmol.2011.210.

PMID:
21825187
7.

The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow.

Lobov IB, Cheung E, Wudali R, Cao J, Halasz G, Wei Y, Economides A, Lin HC, Papadopoulos N, Yancopoulos GD, Wiegand SJ.

Blood. 2011 Jun 16;117(24):6728-37. doi: 10.1182/blood-2010-08-302067. Epub 2011 Apr 15.

8.

Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.

Lutty GA, McLeod DS, Bhutto I, Wiegand SJ.

Invest Ophthalmol Vis Sci. 2011 Jun 8;52(7):4039-47. doi: 10.1167/iovs.10-6798.

9.

Inhibition of vascular endothelial growth factor during the postovulatory period prevents pregnancy in the marmoset.

Fraser HM, Morris KD, Wiegand SJ, Wilson H.

Contraception. 2010 Dec;82(6):572-8. doi: 10.1016/j.contraception.2010.04.020. Epub 2010 Jun 3.

PMID:
21074022
10.

Angiopoietin-2-driven vascular remodeling in airway inflammation.

Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM.

Am J Pathol. 2010 Dec;177(6):3233-43. doi: 10.2353/ajpath.2010.100059. Epub 2010 Oct 15.

11.

A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap.

Cao J, Zhao L, Li Y, Liu Y, Xiao W, Song Y, Luo L, Huang D, Yancopoulos GD, Wiegand SJ, Wen R.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):6009-17. doi: 10.1167/iovs.09-4956. Epub 2010 Jun 10.

12.

VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.

Oliveira HB, Sakimoto T, Javier JA, Azar DT, Wiegand SJ, Jain S, Chang JH.

Eur J Ophthalmol. 2010 Jan-Feb;20(1):48-54.

13.

Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.

Bachmann BO, Luetjen-Drecoll E, Bock F, Wiegand SJ, Hos D, Dana R, Kruse FE, Cursiefen C.

Br J Ophthalmol. 2009 Aug;93(8):1075-80. doi: 10.1136/bjo.2008.145128. Epub 2009 Feb 17.

PMID:
19224901
14.

Vascular endothelial growth factor mediates the estrogen-induced breakdown of tight junctions between and increase in proliferation of microvessel endothelial cells in the baboon endometrium.

Aberdeen GW, Wiegand SJ, Bonagura TW Jr, Pepe GJ, Albrecht ED.

Endocrinology. 2008 Dec;149(12):6076-83. doi: 10.1210/en.2008-0521. Epub 2008 Aug 7.

15.

VEGF blockade inhibits angiogenesis and reepithelialization of endometrium.

Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NR.

FASEB J. 2008 Oct;22(10):3571-80. doi: 10.1096/fj.08-111401. Epub 2008 Jul 7.

16.

The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset.

Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ.

Endocrinology. 2008 Sep;149(9):4413-20. doi: 10.1210/en.2008-0325. Epub 2008 May 22.

PMID:
18499749
17.

Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.

Bachmann BO, Bock F, Wiegand SJ, Maruyama K, Dana MR, Kruse FE, Luetjen-Drecoll E, Cursiefen C.

Arch Ophthalmol. 2008 Jan;126(1):71-7. doi: 10.1001/archopht.126.1.71.

PMID:
18195221
18.

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18363-70. Epub 2007 Nov 13.

19.

Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset.

Taylor PD, Wilson H, Hillier SG, Wiegand SJ, Fraser HM.

Mol Hum Reprod. 2007 Oct;13(10):729-36. Epub 2007 Sep 5.

PMID:
17804434
20.

Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain.

Kasselman LJ, Kintner J, Sideris A, Pasnikowski E, Krellman JW, Shah S, Rudge JS, Yancopoulos GD, Wiegand SJ, Croll SD.

J Vasc Res. 2007;44(4):283-91. Epub 2007 Mar 30.

PMID:
17406120
21.

Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses.

Torres R, Croll SD, Vercollone J, Reinhardt J, Griffiths J, Zabski S, Anderson KD, Adams NC, Gowen L, Sleeman MW, Valenzuela DM, Wiegand SJ, Yancopoulos GD, Murphy AJ.

Pain. 2007 Aug;130(3):267-78. Epub 2007 Mar 26.

PMID:
17379411
22.

Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.

Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24. Epub 2007 Feb 12.

24.

VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets.

Rudge JS, Thurston G, Davis S, Papadopoulos N, Gale N, Wiegand SJ, Yancopoulos GD.

Cold Spring Harb Symp Quant Biol. 2005;70:411-8.

PMID:
16869778
25.

BDNF: a missing link between sympathetic dysfunction and inflammatory disease?

Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, Wiegand SJ, Croll SD.

J Neuroimmunol. 2006 Jun;175(1-2):118-27. Epub 2006 Apr 24.

PMID:
16631934
26.

Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes.

Uemura A, Kusuhara S, Wiegand SJ, Yu RT, Nishikawa S.

J Clin Invest. 2006 Feb;116(2):369-77. Epub 2006 Jan 19.

27.

Expression, localization and hormonal control of angiopoietin-1 in the rhesus macaque endometrium: potential role in spiral artery growth.

Nayak NR, Kuo CJ, Desai TA, Wiegand SJ, Lasley BL, Giudice LC, Brenner RM.

Mol Hum Reprod. 2005 Nov;11(11):791-9. Epub 2006 Jan 3.

PMID:
16390855
28.

Agouti-related protein-deficient mice display an age-related lean phenotype.

Wortley KE, Anderson KD, Yasenchak J, Murphy A, Valenzuela D, Diano S, Yancopoulos GD, Wiegand SJ, Sleeman MW.

Cell Metab. 2005 Dec;2(6):421-7.

29.

Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque.

Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ.

J Clin Endocrinol Metab. 2005 Oct;90(10):5811-8. Epub 2005 Jul 26.

PMID:
16046580
30.

Resistance to diet-induced obesity in mice globally overexpressing OGH/GPB5.

Macdonald LE, Wortley KE, Gowen LC, Anderson KD, Murray JD, Poueymirou WT, Simmons MV, Barber D, Valenzuela DM, Economides AN, Wiegand SJ, Yancopoulos GD, Sleeman MW, Murphy AJ.

Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2496-501. Epub 2005 Feb 7.

31.

Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity.

Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJ.

Nat Med. 2005 Feb;11(2):199-205. Epub 2005 Jan 16. Erratum in: Nat Med. 2005 Mar;11(3):353.

PMID:
15654325
32.

The anti-inflammatory actions of angiopoietin-1.

Thurston G, Rudge JS, Ioffe E, Papadopoulos N, Daly C, Vuthoori S, Daly T, Wiegand SJ, Yancopoulos GD.

EXS. 2005;(94):233-45. Review. No abstract available.

PMID:
15617482
33.

Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function.

Fraser HM, Wilson H, Rudge JS, Wiegand SJ.

J Clin Endocrinol Metab. 2005 Feb;90(2):1114-22. Epub 2004 Nov 23.

PMID:
15562010
34.

Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice.

Blüher S, Moschos S, Bullen J Jr, Kokkotou E, Maratos-Flier E, Wiegand SJ, Sleeman MW, Mantzoros CS.

Diabetes. 2004 Nov;53(11):2787-96. Erratum in: Diabetes. 2005 Jan;54(1):296. Sleemann, Mark W [corrected to Sleeman, Mark W].

35.

Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury.

Hutter R, Carrick FE, Valdiviezo C, Wolinsky C, Rudge JS, Wiegand SJ, Fuster V, Badimon JJ, Sauter BV.

Circulation. 2004 Oct 19;110(16):2430-5. Epub 2004 Oct 11.

PMID:
15477421
36.

Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.

Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW.

Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2666-73.

PMID:
15277490
37.

Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference.

Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ, Sleeman MW.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8227-32. Epub 2004 May 17.

38.

VEGF-mediated inflammation precedes angiogenesis in adult brain.

Croll SD, Ransohoff RM, Cai N, Zhang Q, Martin FJ, Wei T, Kasselman LJ, Kintner J, Murphy AJ, Yancopoulos GD, Wiegand SJ.

Exp Neurol. 2004 Jun;187(2):388-402.

PMID:
15144865
39.

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW.

J Clin Invest. 2004 Apr;113(7):1040-50.

40.

Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice.

Sleeman MW, Garcia K, Liu R, Murray JD, Malinova L, Moncrieffe M, Yancopoulos GD, Wiegand SJ.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14297-302. Epub 2003 Nov 10.

41.

Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation.

Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD.

Cold Spring Harb Symp Quant Biol. 2002;67:267-73. No abstract available.

PMID:
12858549
42.

Activation of the hypothalamic arcuate nucleus predicts the anorectic actions of ciliary neurotrophic factor and leptin in intact and gold thioglucose-lesioned mice.

Anderson KD, Lambert PD, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ.

J Neuroendocrinol. 2003 Jul;15(7):649-60.

PMID:
12787049
43.

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA.

J Cell Physiol. 2003 May;195(2):241-8.

PMID:
12652651
44.

VEGF-dependent conjunctivalization of the corneal surface.

Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP.

Invest Ophthalmol Vis Sci. 2003 Jan;44(1):117-23.

PMID:
12506063
45.

Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells.

Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi H, Honda Y, Wiegand SJ, Yancopoulos GD, Nishikawa S.

J Clin Invest. 2002 Dec;110(11):1619-28.

46.

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD.

Dev Cell. 2002 Sep;3(3):411-23.

47.

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. Epub 2002 Aug 12.

48.
49.

Suppression of diabetic retinopathy with angiopoietin-1.

Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP.

Am J Pathol. 2002 May;160(5):1683-93.

50.

Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.

Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP.

J Clin Invest. 2002 Mar;109(6):805-15.

Supplemental Content

Loading ...
Support Center